Vertex Announces Second Quarter 2021 Financial Results
Vertex receives approval for our fourth cystic fibrosis medicine by Health Canada
New data for investigational gene editing program presented at EHA
Vertex and CRISPR Therapeutics share new clinical data on investigational treatments for severe sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Annual Meeting
View our 2020 Corporate Responsibility Report
Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2020.
COVID-19 Information and Resources
Keeping you informed as the COVID-19 pandemic evolves